In its upcoming report, Lindsay (LNN) is predicted by Wall Street analysts to post quarterly earnings of $1.36 per share, reflecting a decline of 3.6% compared to the same period last year. Revenues are forecasted to be $162.01 million, representing a year-over-year increase of 16.4%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company reve ...

The upcoming report from Nike (NKE) is expected to reveal quarterly earnings of $0.11 per share, indicating a decline of 89.1% compared to the year-ago period. Analysts forecast revenues of $10.67 billion, representing a decrease of 15.4% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's e ...

In its upcoming report, Acuity (AYI) is predicted by Wall Street analysts to post quarterly earnings of $4.31 per share, reflecting an increase of 3.9% compared to the same period last year. Revenues are forecasted to be $1.14 billion, representing a year-over-year increase of 17.5%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this ...

In its upcoming report, McCormick (MKC) is predicted by Wall Street analysts to post quarterly earnings of $0.65 per share, reflecting a decline of 5.8% compared to the same period last year. Revenues are forecasted to be $1.66 billion, representing a year-over-year increase of 1.2%.The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projec ...

The upcoming report from Walgreens Boots Alliance (WBA) is expected to reveal quarterly earnings of $0.34 per share, indicating a decline of 46% compared to the year-ago period. Analysts forecast revenues of $36.66 billion, representing an increase of 0.9% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earn ...

Group 1 - Paramount Resources began as a dry gas producer in Canada and reports using Canadian dollars [2] - The oil and gas industry is characterized as a boom-bust, cyclical industry requiring patience and experience [2] Group 2 - The analysis focuses on identifying undervalued companies in the oil and gas sector, including balance sheet evaluation, competitive positioning, and development prospects [1]

Key Takeaways Ford's 0.26X forward P/S is below its 5-year average and peers GM and Tesla despite a YTD stock gain. Ford Pro's strong demand, paid software growth and Super Duty launch drive optimism for future earnings. EV losses, ICE slowdown and $1.5B in tariff impact weigh on Ford's 2025 earnings outlook and estimates.U.S. legacy automaker Ford (F) is currently trading at a 0.26 forward 12-month price-to-sales (P/S) ratio, below the industry levels as well as its own 5-year average. The valuation also ...

Company Overview - Tango Therapeutics, Inc. (TNGX) shares increased by 7.5% to close at $5.16, with notable trading volume compared to typical sessions, and a total gain of 157.4% over the past four weeks [1][2] Pipeline Developments - The company recently dosed the first patient in the TNG456 phase I/II study targeting MTAP-deleted solid tumors, particularly glioblastoma, which has contributed to positive market sentiment regarding its pipeline of precision cancer medicines [2] Financial Expectations - Tango Therapeutics is projected to report a quarterly loss of $0.36 per share, reflecting a year-over-year decline of 50%, with expected revenues of $5.79 million, down 70.9% from the previous year [3] - The consensus EPS estimate for the quarter has been revised slightly higher in the last 30 days, indicating a potential for price appreciation if the trend continues [4] Industry Context - Tango Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where it holds a Zacks Rank of 3 (Hold) [5] - Another company in the same industry, Protagonist Therapeutics (PTGX), experienced a 1.1% decline in its stock price, with a monthly return of 17.5% [5][6]

Core Insights - Chevron Corporation is focusing on the Gulf of America (GOA) for its production growth, targeting 300,000 net barrels of oil equivalent per day (BOE/d) by 2026, a 50% increase from 2020 levels [1][10] - The company is utilizing new technologies and operational experience to enhance efficiency and reduce emissions in deepwater resource extraction [2][3] Production Developments - The Ballymore asset is expected to produce approximately 75,000 barrels per day once fully operational, while the Whale project aims for 100,000 BOE/d at peak production [1] - The Anchor platform, operational since August 2024, is designed for extreme conditions and has an estimated resource base of 440 million barrels of oil-equivalent [2] Strategic Approach - Chevron is implementing updated project models to lower costs and extend the operational life of its fields, exemplified by the Tahiti platform, which has produced over 500 million barrels since 2009 and could continue into the 2040s [3] - The focus is on smarter drilling practices, emphasizing efficiency and low-carbon intensity output [3] Competitive Landscape - Shell plc is the largest operator in the GOA, known for its advanced technology and sustainability efforts, achieving a 40% reduction in methane emissions since 2016 [4] - BP plc is also a significant player in the GOA, with plans to invest $7 billion through 2025 to exceed 400,000 BOE/d by the end of the decade [5]

Key Takeaways E is selling a 20% stake in Plenitude to Ares for 2 billion euros. The deal supports the satellite model of Eni to grow low-carbon businesses with long-term partners. Plenitude plans to grow renewable capacity to 10 GW and expand beyond 11M customers by 2028.Italian energy major Eni S.p.A. (E) has signed a landmark agreement to sell a 20% stake in its multi-energy unit Plenitude to Ares Management Alternative Credit funds for approximately €2 billion. According to the company, the deal value ...